NCT04599816View on ClinicalTrials.gov

Levosimendan Administration in Pulmonary Hypertension

NACompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 17, 2020

Primary Completion Date

October 17, 2022

Study Completion Date

October 17, 2022

Conditions
Hypertension, PulmonaryCardiac FailurePulmonary Vascular Resistance Abnormality
Interventions
DRUG

levosimendan at a dose of 3 mcg/kg

levosimendan will be administered intravenously at a dose of 3 mcg/kg after anesthesia induction

DRUG

levosimendan at a dose of 6 mcg/kg

levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction

DRUG

levosimendan at a dose of 12 mcg/kg

levosimendan will be administered intravenously at a dose of 12 mcg/kg after anesthesia induction

Trial Locations (1)

17674

Onassis Cardiac Surgery Center, Athens

All Listed Sponsors
lead

Aretaieion University Hospital

OTHER

NCT04599816 - Levosimendan Administration in Pulmonary Hypertension | Biotech Hunter | Biotech Hunter